Rise In Demand For Cell And Genetic Therapy Fuels Biologics CDMO Market Growth Is Supporting Development Across The Biologics CDMO Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Biologics CDMO Market Progress Through 2030?

The biologics cdmo market has experienced significant growth in recent years. Its value is expected to rise from $24.15 billion in 2025 to $27.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.1%. Historically, this expansion has been driven by increased biologics research, advancements in cell culture technologies, a growing incidence of chronic diseases, the development of biosimilar pipelines, and government support for biopharma manufacturing.

The biologics CDMO market is projected for substantial expansion over the next few years. Its size is anticipated to reach $48.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.9%. This projected growth during the forecast period is attributable to several factors, including a surge in gene and cell therapy development, the adoption of automation and robotics in CDMO processes, an expansion of global biologics manufacturing capacity, increasing investment in precision medicine, and a rising demand for cost-effective biologics. Key trends expected within the forecast timeframe encompass the expansion of biologics CDMO services, growth in mammalian cell-based production, an increase in the outsourcing of gene therapy manufacturing, the adoption of advanced bioprocessing techniques, and a rising demand for biosimilars.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Market Drivers Are Helping Shape The Biologics CDMO Market Expansion?

The increasing need for cell and genetic therapy is anticipated to drive expansion in the biologic CDMO market. Cell and gene therapies represent groundbreaking medical strategies, employing living cells or genetic material to target the root causes of diseases at a cellular or genetic level. This offers promising treatments for conditions often challenging or impossible to cure with conventional drugs, leading to a growing demand for these therapies due to their potential to provide novel solutions by addressing fundamental genetic or cellular issues. Biologic CDMOs offer specialized knowledge in managing living cells, viral vectors, and genetic material. This enables the secure and effective manufacture of cell and gene therapies, supporting biopharmaceutical firms through regulatory complexities and technical hurdles, thus accelerating the transition from laboratory research to clinical implementation. A notable example is observed in March 2024, when IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, reported that global expenditures on cell and gene therapies reached $5.9 billion in 2023, marking a significant 38% increase from 2022. Consequently, this heightened demand for cell and genetic therapy is a key factor propelling the expansion of the biologic CDMO market.

What Key Segment Areas Are Included In The Biologics CDMO Market Assessment?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Which Trends Are Affecting The Biologics CDMO Market Framework?

Leading companies within the biologics CDMO market are actively developing sophisticated technological solutions, such as innovative cell lines, to bolster the efficiency and capabilities of biopharmaceutical development and manufacturing. This technology is capable of producing therapeutic antibodies with significantly enhanced potency, thereby addressing crucial challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a manufacturing company based in Switzerland specializing in the pharmaceutical and biotechnology sectors, unveiled GS Effex cell lines. These were specifically designed to yield antibodies that are 100% free of fucose, a sugar molecule, and demonstrate increased potency without compromising other performance attributes. This innovation helps to overcome immunotherapy research and development challenges related to the necessity for antibody therapeutics to boost their potency. It is a stable, scalable, and productive cell line that offers a comprehensive solution for therapeutic development, spanning from discovery-stage research through to commercial manufacturing.

Which Companies Form The Competitive Landscape Of The Biologics CDMO Market?

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Access The Complete Biologics CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Is The Dominant Market In The Biologics CDMO Market?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biologics CDMO Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2026, By The Business Research Company

Biologics Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795